Clinical research of autologous hematopoietic stem cell transplantation for hematological malignancies and solid tumors
- VernacularTitle:自体造血干细胞移植治疗恶性血液病及实体瘤的临床研究
- Author:
Zhenqian HUANG
;
Donghua ZHANG
;
Huo TAN
- Publication Type:Journal Article
- Keywords:
Hematopoietic stem cell transplantation,autologous;
Hematological malignancies;
Solid tumor
- From:
Chinese Journal of Practical Internal Medicine
2006;0(23):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the therapeutic effect of autologous hematopoietic stem cell transplantation(AHSCT)on hematological malignancies and solid tumors.Methods Twenty patients with age from 18 to 50 years received AHSCT.Two or 3 of following agents,Cytarabine(Ara-C)3～4 g/m2,Cyclophosphamide(CTX)4～6 g/m2,Etoposide(VP-16)0.5～1.0 g/m2,Semustine(me-CCNU)300 mg/m2,Melphalan(Mel)140 mg/m2,Thiotep a(TSPA)600 mg/m2,Carboplatin(CBP)1.0 g/m2,Busulfan 16mg/kg,were combined as conditioning regimen in all patients.Among them 2 patients with ALL accepted additional total body irradiation(TBI).Results All the patients have reconstituted bone marrow hematopoiesis after transplantation.None of them had the transplantation-related mortality.Among 20 patients with CML and malignant lymphoma,15 achieved disease-free survival(DFS)with a median survival time of 39.5(2～109)months.Conclusion AHSCT might represent an effective approach to the treatment of some patients with chemosensitive solid tumor who are complete remission or part remission.It is suggested that the patients have got a obvious survival benefit from AHSCT.
